An example technique for treating a skin cancer condition includes administering a therapeutically effective amount of a p53-related protein kinase (PRPK) inhibitor to a patient having skin cancer or having a high risk of developing skin cancer. An example composition includes a therapeutically effective amount of a PRPK inhibitor for treating a skin cancer condition. An example composition includes a pharmaceutically effective amount of at least one anti-solar ultraviolet (anti-sUV) combination for preventing a skin cancer condition. The at least one anti-sUV combination is chosen from the combinations: avobenzone and octinoxate； octocrylene and zinc oxide； avobenzone, octocrylene, and titanium dioxide； or avobenzone, octocrylene, and zinc oxide.
